Characterization of trans- and cis-cleavage activity of the SARS coronavirus 3CLpro protease: basis for the in vitro screening of anti-SARS drugs  by Lin, Cheng-Wen et al.
FEBS 28759 FEBS Letters 574 (2004) 131–137Characterization of trans- and cis-cleavage activity of the
SARS coronavirus 3CLpro protease: basis for the in
vitro screening of anti-SARS drugsCheng-Wen Lina,b,*, Chang-Hai Tsaic,*, Fuu-Jen Tsaic, Pei-Jer Chend,
Chien-Chen Laic, Lei Wanc, Hua-Hao Chiua, Kuan-Hsun Lina
aDepartment of Medical Laboratory Science and Biotechnology, China Medical University, No. 91, Hsueh-Shih Road, Taichung 404, Taiwan, ROC
bClinical Virology Laboratory, Department of Laboratory Medicine, China Medical University Hospital, Taichung 404, Taiwan, ROC
cDepartment of Medical Genetics and Medical Research, China Medical University Hospital, Taichung 404, Taiwan, ROC
dDepartment of Internal Medicine, National Taiwan University College of Medicine, National Taiwan University Hospital, Taipei 100, Taiwan, ROC
Received 6 July 2004; revised 26 July 2004; accepted 12 August 2004
Available online 21 August 2004
Edited by Valdimir SkulachevAbstract Severe acute respiratory syndrome (SARS) has been
globally reported. A novel coronavirus (CoV), SARS-CoV, was
identiﬁed as the etiological agent of the disease. SARS-CoV 3C-
like protease (3CLpro) mediates the proteolytic processing of
replicase polypeptides 1a and 1ab into functional proteins,
playing an important role in viral replication. In this study, we
demonstrated the expression of the SARS-CoV 3CLpro in
Escherichia coli and Vero cells, and then characterized the in
vitro trans-cleavage and the cell-based cis-cleavage by the
3CLpro. Mutational analysis of the 3CLpro demonstrated the
importance of His41, Cys145, and Glu166 in the substrate-
binding subsite S1 for keeping the proteolytic activity. In
addition, alanine substitution of the cleavage substrates indicated
that Gln-P1 in the substrates mainly determined the cleavage
eﬃciency. Therefore, this study not only established the quan-
tiﬁable and reliable assay for the in vitro and cell-based
measurement of the 3CLpro activity, but also characterized the
molecular interaction of the SARS-CoV 3CLpro with the
substrates. The results will be useful for the rational development
of the anti-SARS drugs.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Severe acute respiratory syndrome (SARS) with high fever,
malaise, headache, dry cough. and a progress of generalized,
interstitial inﬁltrates in the lung has recently been reported
over 32 countries around the world, including Taiwan, China,
Hong Kong, Vietnam, and Canada [1–4]. SARS was rapidly* Corresponding authors. Fax: +886-4-22057414 (C.-W. Lin).
E-mail address: cwlin@mail.cmu.edu.tw (C.-W. Lin).
Abbreviations: SARS, severe acute respiratory syndrome; CoV, coro-
navirus; 3CLpro, 3C-like protease; S-I (II), substrate-I (II); Luc,
luciferase
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doi:10.1016/j.febslet.2004.08.017transmitted through aerosols, causing 8447 reported cases with
811 deaths worldwide in a short period from February to June,
2003 [5–7]. For successful control of the SARS outbreak, de-
veloping eﬀective therapies and vaccines becomes medically
important eﬀorts.
A novel coronavirus (CoV), SARS-coronavirus (SARS-
CoV), was identiﬁed as the etiological agent of the disease [1–4].
SARS-CoV particles contain a single positive-stranded RNA
genome that is approximately 30 kb in length and has a 50 cap
structure and 30 poly(A) tract [8–10]. The SARS-CoV genome
encodes for replicase, spike, envelope, membrane, and nucleo-
capsid. The replicase gene encodes two large overlapping
polypeptides (replicase 1a and 1ab, 450 and 750 kDa, re-
spectively), including 3C-like protease (3CLpro), RNA-depen-
dent RNA polymerase, and RNA helicase for viral replication
and transcription [11]. The SARS-CoV 3CLpro mediates the
proteolytic processing of replicase polypeptides 1a and 1ab into
functional proteins, playing an important role in viral replica-
tion. Eleven cleavage sites of the 3CLpro on the viral polyprotein
have been mapped using the computer prediction based on the
substrate conservation among CoV main proteases [12], being
conﬁrmed by the in vitro trans-cleavage of 11 substrate peptides
[13]. Therefore, the SARS-CoV 3CLpro becomes an attractive
target for developing eﬀective drugs against SARS.
In this study, we characterized the in vitro trans-cleavage
and the cell-based cis-cleavage with the SARS-CoV 3CLpro
(Fig. 1A and B). For the trans-cleavage assay, the functional
3CLpro and three mutants at the substrate-binding sites were
used to test their proteolytic activity with the cleavage sub-
strate-I (S-I, TVRLQAGNAT) fused at the N-terminus of the
SARS-CoV non-structure protein 7 (nsp7). For the cis-cleav-
age assay, the in-frame construction of the 3CLpro, the sub-
strate-II (S-II, SAVLQSGFRK), and the luciferase (Luc) was
transfected into the Vero cells. In addition, the mutations at
the substrate conserved residues Leu and Gln were performed
for the examination of the substrate speciﬁcity. In this study,
the in vitro trans-cleavage and cell-based cis-cleavage activities
of the SARS-CoV 3CLpro had been determined using the
quantitative methods of an Enzyme-Linked Immunosorbent
Assay (ELISA) and a Luc assay, which will be useful for large-
scale screening of inhibitors against SARS.blished by Elsevier B.V. All rights reserved.
Fig. 1. Flowcharts for the in vitro trans-cleavage ELISA assay (A) and the cell-based cis-cleavage Luc assay (B). For trans-cleavage assay (A), the
substrate-I/nsp7 (S-I/nsp7) gene was cloned into the pET43.1b expression vector for generation of the in-frame S Tag-nsp7-HSV Tag fusion proteins
in E. coli. Subsequently, the trans-cleavage product of the fusion protein S-I/nsp7 by the 3CLpro and the mutants (H41A, C145A, and E166R) was
captured onto the anti-HSV mAb coated microwells. The non-cleavage fusion protein was detected using the S protein-HRP conjugate and ABTS/
H2O2 substrates. For cis-cleavage assay (B), the in-frame construction of the 3CL
pro, the substrate-II, and Luc plus the pEGFP-N1 was transfected
into the Vero cells. The Luc activity was referred to monitor the cis-cleavage of the fusion protein, the 3CLpro-S-II-Luc.
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2.1. Construction, expression, and puriﬁcation of SARS-CoV 3CLpro
The 3CLpro gene located within the nucleotides 9985–10 902 of the
SARS-CoV TW1 strain genome (GenBank Accession No. AY291451)
[14] was ampliﬁed using the reverse-transcriptase polymerase chain
reaction (RT-PCR) with speciﬁc primers 50-CCCGGATCCAGTG-
GTTTTAGGAAAATGGCATTC-30 and 50-GGTGCTCGAGTTGG-
AAGGTAACACCAGAGCATTG-30. The forward primer mentioned
above contained an EcoRI restriction site and the reverse primers in-
cluded an XhoI restriction site. Each RT-PCR product was digested
with EcoRI and XhoI, and then ligated into the EcoRI/XhoI cleavage
sites of the pET24a vector (Novagen) and expressed as a histidine tag
fusion protein. The Escherichia coli strain BL21(DE3) was transformed
with the resulting plasmid, pET24a-3CLpro, then cultured in LB me-
dium in the presence of 100 g of kanamycin per ml at 37 C. Once the
cultures reached an absorbance of 0.5–0.6 at 600 nm, they were in-
duced by the addition of 4 mM isopropyl-b-D-thiogalactopyranoside
for 4 h at 22 C. Finally, the bacteria were harvested by centrifugation
at 10 000 rpm for 15 min at 4 C and resuspended in the 10 mM im-
idazole Bind buﬀer for sonication. The supernatant was puriﬁed with
the HisTrap Kit and buﬀer kit (Amersham) after centrifugation
(10 000 g for 20 min). The concentration of the puriﬁed protein was
determined using the Bio-Rad protein assay reagent.
2.2. SDS–PAGE and Western blotting
The samples from fractions of each puriﬁcation step were then dis-
solved in 2 SDS–PAGE sample buﬀer without 2-mercaptoethanol
and boiled for 10 min. Proteins were resolved on 12% SDS–PAGE gels
and stained with Coomassie Brilliant Blue (Sigma). Moreover, the
electrophoretically separated proteins were transferred to nitrocellu-
lose paper. The resultant blots were blocked with 5% skimmed milk
and then reacted with the appropriately diluted Anti-His Tag mono-clonal antibody (mAb) (Serotec) for a 3-h incubation. The blots were
then washed with 1% TBS containing 0.05% Tween 20 (TBST) three
times and overlaid with a 1/5000 dilution of goat anti-mouse IgG
antibodies conjugated with alkaline phosphatase (Perkin–Elmer Life
Sciences, Inc.). Following a 1-h incubation at room temperature, the
blots were developed with TNBT/BCIP (Gibco).
2.3. Azocasein digestion of SARS-CoV 3CLpro
The protease activity of the SARS-CoV 3CLpro was determined
spectrophotometrically following the digestion of azocasein (Sigma) as
the substrate [15]. 150 ll of samples was added to 150 ll of chromogen
reagent containing 2% azocasein in 50 mM Tris–HCl, pH 8.5. After 2-
h incubation at 37 C, non-digested azocasein was precipitated by
adding 350 ll of 10% trichloroacetic acid (TCA) (Merck). For deter-
mining the proteolytic activity, 350 ll of the resulting supernatants
centrifuged at 10 000 g for 10 min, was mixed with 300 ll of 1 N
NaOH, and then the absorbance of the above mixture at 440 nm was
measured. The blank was obtained by precipitating the substrate plus
the sample in TCA without incubation.
2.4. Site-directed mutagenesis of SARS-CoV 3CLpro
His41, Cys145, and Glu166 within the catalytic sites of the SARS-
CoV 3CLpro protein were mutated by the PCR method similar to our
previous report [16]. Site-directed mutagenesis was conducted by using
paired complementary oligonucleotides for the desired point mutations
to generate speciﬁc mutations into the SARS-CoV 3CLpro protein. The
pairs of primers used were 50-TGTCCAAGAGCCGTCATTTGC-30
and 50-GCAAATGACGGCTCTTGGACA-30 for the substitution of
His41 with alanine, 50-AATGGATCAGCCGGTAGTGTT-30 and 50-
AACACTACCGGCTGATCCATT-30 for the replacement of Cys145
by alanine, and 50-CATCATATGCGGCTTCCAACA-30 and 50-
TGTTGGAAGCCGCATATGATG-30 for the mutation of Glu166
with arginine. The correct sequence of each mutant of the SARS-CoV
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analysis.
2.5. Construction and expression of SARS-CoV nsp7 fusion protein
The nsp7 gene located in the nucleotides 12 937–13 356 of the TW1
strain genome. The cleavage S-I (TVRLQAGNATE) for the 3CLpro
protein located within the junction of nsp6 and nsp7, being fused at the
N-terminus of the nsp7 protein (Fig. 1A). The S-I/nsp7 gene was
ampliﬁed using PCR with speciﬁc paired primers 50-CGTGGATCCG-
GCTACAGTACGTCTTCAGGCT-30 and 50-CGCaagcttGCGGAG-
TTGGTCACAACTACA-30. The forward primer mentioned above
contained a BamHI restriction site and the reverse primers included a
HindIII restriction site. Each RT-PCR product was digested with
BamHI and HindIII, and then ligated into the BamHI/HindIII cleav-
age sites of the pET43.1b vector (Novagen). The resultant plasmids
were transformed into the E. coli strain BL21(DE3). The S-I/nsp7
fusion protein expressed in E. coli was puriﬁed using the HisTrap Kit
(Amersham).
2.6. In vitro trans-cleavage activity of the 3CLpro determined by ELISA
For determining the trans-acting proteolytic assay, the SARS-CoV
3CLpro reacted with the S-I/nsp7 fusion protein captured onto the
microtiter plates (Fig. 1A). The wells of a 96-well plate were coated
with 100 ll of diluted anti-HSV mAb (Novagen) and incubated
overnight at 4 C. Following each incubation and subsequent layer of
the ELISA, the wells were washed three times with TBST. After
blocking by incubation with 5% skimmed milk in TBST for 2 h at
room temperature (200 ll/well), 100 ll of the mixture containing the S-
I/nsp7 fusion protein (10 lg/ml) and the 3CLpro (300 lg/ml) was added
into anti-HSV mAb-coated wells for the 3-h incubation. The intact
form of the S-I/nsp7 fusion protein was detected using the S protein
conjugated to peroxidase (Novagen) for 1 h at room temperature. The
ELISA products were developed with a chromogen solution contain-
ing 2,20-azino-di-(3-ethylbenzthiazoline-6-sulfonate) (ABTS) and hy-
drogen peroxide. The relative trans-cleavage activity was calculated as
1 ) ðA4053CLpro Þ=ðA405no 3CLpro Þ.2.7. The cell-based cis-cleavage activity of the 3CLpro
For examining the cis-acting proteolytic assay, the 3CLpro was fused
in-frame with a cleavage site and a Luc at the C-terminus (Fig. 1B).
The 3CLpro gene was ampliﬁed using PCR with the paired primers
50-CCCGGATCCAGTGGTTTTAGGAAAATGGCATTC-30 and 50-
TGCAGAATTCTTTCCTAAAACCACTCTGCAGAACAGCAGA-
TTGGAAGGTAACACCAGAGCATTG-30. The forward primer
mentioned above contained a BamHI restriction site and the reverse
primer included an EcoRI restriction site and an in-frame gene en-
coding for the C-terminus of the 3CLpro and the S-II (SAV-
LQSGFRK). The PCR product was digested with BamHI and EcoRI,
and then cloned into the pcDNA3.1 vector (Amersham). The resulting
plasmid was named as Pro/S-II. Meanwhile, the substitutions of Leu
and Gln in the S-II by alanine with the plasmid Pro/S-II were also
constructed using the reverse primers 50-TGCAGAATTCTTTCCTA-
AAACCACTCTGCGCAACAGCAGA-30 and 50-TGCAGAATTCT-
TTCCTAAAACCACTCGCCAGAACAGCAGA-30, which plasmids
were designed as Pro/S-II(LﬁA) and Pro/S-II(QﬁA), respectively.
Subsequently, the ﬁreﬂy Luc gene in the pGL3(R2.1)-Basic vector
(Promega) was ampliﬁed by PCR with the primers 50-GGTGGAATT-
CATGGAAGACGCCAAAAACATAAAG-30 and 50-TAGACTCG-
AGTTACACGGCGATCTTTCCGCCCTT-30. The Luc gene was
cloned into the EcoRI/XhoI restriction enzyme sites of the plasmids
Pro/S-II, Pro/S-II(LﬁA) and Pro/S-II(QﬁA). These recombinant
plasmids were designed as Pro/S-II/Luc, Pro/S-II(LﬁA)/Luc and Pro/
S-II(QﬁA)/Luc for detecting the cis-acting proteolytic activity of the
3CLpro in Vero cells. Vero cells at 60–90% conﬂuency in 6-well plates
were transfected with 5 lg of total plasmids (0.5 lg of the indicated
expression vector pEGFP-N1 plus 4.5 lg of pcDNA3.1), Pro/S-II, Pro/
S-II/Luc, Pro/S-II(LﬁA)/Luc or Pro/S-II(QﬁA)/Luc, using the
GenePorter reagent. According to the manufacturer’s direction (Gene
Therapy Systems, San Diego, CA), the transfected cells were main-
tained in 2 ml of Dulbeccos modiﬁed Eagle’s medium (DMEM) con-
taining 20% bovine serum (FBS) after 5-h incubation with the mixture
of the plasmid DNA and GenePorter reagent. Transfected cells were
selected using the DMEM containing 10% FBS and 800 lg/ml of G418
for one month, and then G418-resistant cell clones were conﬁrmed by
the expression of green ﬂuorescent protein (EGFP). Fireﬂy Luc ac-tivity in the transfected cells was measured using the dual Luciferase
Reporter Assay System (Promega) and the Luminometer TROPIX
TR-717 (Applied Biosystems).3. Results
3.1. Expression and puriﬁcation of the recombinant SARS-CoV
3CLpro in E. coli
To examine the expression of the 3CLpro protein in E. coli,
the C-terminal His tagged 3CLpro protein was detected using
Western blotting with anti-His Tag monoclonal antibody.
Western blot revealed that a 34-kDa protein in the supernatant
and the pellet fractions was found in the recombinant E. coli
(data not shown). The 34-kDa recombinant protein was in
agreement with the theoretical molecular weight (33.8 kDa) of
the recombinant 3CLpro fusion protein using the Compute pI/
Mw tool (http://tw.expasy.org).
Subsequently, the soluble 3CLpro protein expressed in the
E. coli was harvested from the supernatant of the sonicated
cells and then puriﬁed using the immobilized-metal aﬃnity
chromatography (IMAC). The Coomassie blue-stained gel
revealed that one major band of the recombinant 3CLpro
protein was eluted with imidazole ranging from 100 to 500
mM (Fig. 2A, lanes 5–9). The high purity of the 3CLpro was
observed in the last eluted fraction with 500 mM imidazole
(Fig. 2A, lane 9). Interestingly, Western blotting demon-
strated that an about 68-kDa immuno-reactive band, except a
34-kDa band, was found at more than 200 lg/ml concen-
tration of our puriﬁed 3CLpro, which was in the eluted
fraction with imidazole ranging from 300 to 500 mM (Fig.
2B, lanes 5–7). However, no 68-kDa immuno-reactive band
was observed at lower than 200 lg/ml concentration, being in
the eluted fraction with 200 mM imidazole (Fig. 2B, lane 4).
The result was in agreement with a previous report in which
the puriﬁed SARS-CoV 3CLpro existed at more than 200 lg/
ml protein concentration as a mixture of the inactive
monomer (major) and the active dimer (minor) [13].3.2. Azocasein hydrolysis of the SARS-CoV 3CLpro
To test the protease activity of the recombinant 3CLpro
protein, the azocasein hydrolysis of the 3CLpro protein in each
eluted fraction was further performed (Fig. 2C). The azocasein
proteolytic proﬁle revealed that the 3CLpro protein with a high
purity eluted at 500 mM imidazole has highest proteolytic
activity compared to those eluted fractions at 20, 40, 60, 100,
and 300 mM imidazole (Fig. 2C). Moreover, the azocasein
proteolytic assay showed a dose-dependent ability of the
3CLpro protein using the serial 2-fold dilution ranging from
200 to 800 lg/ml (data not shown). The results showed the
enzyme activity of the puriﬁed 3CLpro protein.3.3. In vitro trans-cleavage activity of the 3CLpro
The proteolytic speciﬁcity of the SARS-CoV 3CLpro was
examined using the in vitro trans-cleavage of the S-I
(TVRLQAGNATE mapped at the junction of nsp6 and nsp7).
The S-I was fused in-frame with a Nus-Tag and an S-Tag at
the N-terminus and the nsp7 and an HSV-Tag at the C-ter-
minus (Fig. 1A). According to the structure knowledge [17],
mutations of His-41 by Ala (H41A), Cys-145 by Ala (C145A),
and Glu166 by Arg (E166R) within the substrate-binding site
Fig. 2. SDS–PAGE (A), Western blotting (B), and enzyme activity (C) of the recombinant SARS-CoV 3CLpro in each puriﬁed step. (A) The su-
pernatant of the sonicated cells transformed with the pET24a-3CLpro plasmid was puriﬁed by IMAC. 20 ll of each eluted fraction was analyzed by
12% SDS–PAGE with Coomassie blue staining. Lanes 2–9 indicated that the samples from the fractions eluted with 20, 40, 60, 100, 200, 300, 400, and
500 mM imidazole, respectively. Lane 1 was the molecular marker. kDa, kilodaltons. (B) 5 ll of each eluted fraction was analyzed by 12% SDS–
PAGE, then electrophorectically transferred onto nitrocellulose paper. The blot was probed with mouse anti-His tag antibodies, and developed with
an alkaline phosphatase-conjugated secondary antibody and NBT/BCIP substrates. Lanes 2–7 indicated that the samples from the fractions eluted
with 60, 100, 200, 300, 400, and 500 mM imidazole, respectively. (C) The digestion of azocasein by the 3CLpro protein was measured at 440 nm. The
blank was obtained by precipitating the substrate plus the sample in TCA without incubation.
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activity. The trans-cleavage of the S-I/nsp7 fusion protein (Nus
Tag/S-Tag/S-I/nsp7/HSV-Tag) by the 3CLpro and the mutants
was analyzed using the Western blotting with the S-protein
conjugated to peroxidase. An immuno-band for the cleavage
product, the Nus Tag/S-Tag protein, was detected in the trans-cleavage by 3CLpro, but not in the reactions by the 3CLpro
mutants H41A, C145A, and E166R (data not shown). For
quantiﬁcation of the in vitro trans-cleavage, the mixture of the
3CLpro and the S-I/nsp7 fusion protein was incubated in the
anti-HSV mAb-coated wells. Subsequently, the non-cleavage
form of the S-I/nsp7 fusion protein was captured and then
Fig. 3. ELISA for the trans-cleavage of the S-I/nsp7 fusion protein by
the 3CLpro and the mutants H41A, C145A, and E166E. After a 3-h
incubation, the mixture of the fusion protein Nus-Tag/S-Tag/S-I/nsp7/
HSV-Tag and the 3CLpro was added into the anti-HSV mAb-coated
wells. The inhibitor ABF was also added into the trans-cleavage assay.
The non-cleavage S-I/nsp7 fusion protein captured onto 96-well plates
with anti-HSV mAb was detected using the S protein-HRP conjugate
and ABTS/H2O2 substrates. The ELISA product was measured at
A405 nm. The relative trans-cleavage activity was calculated as
1 ) ðA4053CLpro Þ=ðA405no 3CLpro Þ.
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peroxidase (Fig. 3). The relative trans-cleavage ability revealed
that the 3CLpro mutants H41A, C145A, and E166R lose more
than 50% activity compared to the wild type 3CLpro. Fur-
thermore, the enzyme activity of the 3CLpro was signiﬁcantly
inhibited by the serine protease inhibitor 4-(2-aminoeth-
yl)benzenesulfonyl ﬂuoride hydrochloride (ABF) (Fig. 3).
These results demonstrated the trans-cleavage speciﬁcity of the
3CLpro and the importantly functional role of the residues
His41, Cys145, and Glu166 within the substrate-binding site
S1.
3.4. cis-cleavage activity of the 3CLpro in the cell-based assays
For the cell-based cis-cleavage assay, the in-frame con-
struction (Pro/S-II/Luc) of the 3CLpro, the S-II (SAV-
LQSGFRK), and the Luc plus pEGFP-N1 was transfected
into Vero cells (Fig. 4D). Since the fusion of the ﬁreﬂy Luc
with a more than 30 kDa protein fused as the N-terminus
resulted in a dramatic decrease of Luc activity [18], the de-
tection of Luc activity could be referred to the measurement
of the cis-cleavage by the SARS-CoV 3CLpro. For examining
the substrate speciﬁcity, alanine substitution of the substrate
conserved residues Leu-P2 and Gln-P1, designed as Pro/S-
II(LﬁA)/Luc and Pro/S-II(QﬁA)/Luc, were also carried
out (Fig. 4E and F). Western blotting of the cell lysates with
the anti-His Tag mAb demonstrated that three immuno-
bands, a 94-kDa band for the fusion protein 3CLpro/S-II/Luc,
a 68-kDa band for the 3CLpro dimer and a 34-kDa band for
the 3CLpro monomer, were clearly observed in the Vero cells
transfected with Pro/S-II/Luc, Pro/S-II(LﬁA)/Luc, and Pro/
S-II(QﬁA)/Luc (data not shown). However, the relative Luc
activity in the transfected cells showed that the Vero cells
transfected with the plasmid Pro/S-II/Luc (100 689 408 light
units) showed 4- and 25-fold higher Luc activity compared tothe cells carrying Pro/S-II(LﬁA)/Luc (23 972 582 light
units) and Pro/S-II(QﬁA)/Luc (3780 282 light units), re-
spectively (Fig. 4G). The results demonstrated the cis-cleav-
age of the fusion protein 3CLpro/substrate-II/Luc. Moreover,
mutational analysis indicated that the conserved residue Gln
at the P1 position mainly determined the substrate cleavage
eﬃciency of the 3CLpro.4. Discussion
In this study, we demonstrated the expression and functional
activity of the SARS-CoV 3CLpro in E. coli and Vero cells, and
also characterized the trans- and cis-cleavage of the substrates
TVRLQAGNAT and SAVLQSGFRK in the fusion proteins
by the 3CLpro. In addition, we examined the active site SI and
substrate speciﬁcity of the 3CLpro using site-directed muta-
genesis, providing the insight into molecular recognition of the
SARS-CoV 3CLpro with the substrates for the rational design
of anti-SARS drugs.
Our results indicated that the recombinant SARS-CoV
3CLpro exists as a mixture of monomers (major) and dimers
(minor) in the solutions (Fig. 2B), being in agreement with
other studies on the recombinant protease of human CoV
(HCoV) and the related porcine transmissible gastroenteritis
(corona)virus (TGEV) [19,20]. Furthermore, alanine substitu-
tion at the Cys145–His41 catalytic dyad resulted in a signiﬁ-
cant loss of the 3CLpro enzyme activity (Fig. 3), revealing the
importance of the Cys145–His41 catalytic dyad. According to
the crystallographic data [17], the Glu166 in the substrate-
binding subsite, SI, of the SARS-CoV 3CLpro has a salt bridge
with His172 and hydrogen bonds with the NH group of the
other monomer Ser1, being important for the substrate bind-
ing and the 3CLpro dimerization. Mutational analysis of
Glu166 conformed the importance of Glu166 in the enzymatic
function of the SARS-CoV 3CLpro (Fig. 3). These results
showed the important role of the substrate-binding subsite S1
in the anti-SARS drug design.
The identiﬁed cleavage site of the SARS-CoV 3CLpro con-
tains a LQA(S,N) motif recognized by most other CoV pro-
teases [12,21], which leads us to suggest that the proteolytic
processing of the SARS-CoV replicase polyproteins could be
similar to those of other CoVs, such as HCoV and TGEV.
Based on the conserved LQA(S,N) motif, Leu-P2 and Gln-P1
were selected for mutational analysis of the substrate speci-
ﬁcity by the 3CLpro. Alanine substitution at Leu-P2 and Gln-P1
revealed that Gln-P1 dominantly determined the cleavage eﬃ-
ciency of the substrates by the SARS-CoV 3CLpro (Fig. 4G).
We will further characterize the substrate speciﬁcity by the
systematically mutational analysis for the molecular-based
design on the anti-SARS drugs.
In this study, we establish the in vitro trans-cleavage assay
and the cell-based cis-cleavage assay with the recombinant
3CLpro protein. The azocasein and the substrate fusion protein
Nus-Tag/S-Tag/S-I/nsp7/HSV-Tag were used as the substrates
in the in vitro trans-cleavage assay, providing the rapid and
quantiﬁable assay for large-scale screening of SARS-CoV
3CLpro inhibitors. Furthermore, the Luc activity referred to
the cell-based cis-cleavage activity will be useful for the ex-
amination of the inhibitory eﬀects on the SARS-CoV 3CLpro
in the Vero cells. Therefore, this study not only characterizes
Fig. 4. Expression of the in-frame gene 3CLpro/S-II/Luc for the cis-cleavage analysis. (A–F) Microscopical analysis of the Vero cells with bright ﬁeld
(left) and ﬂuorescent light (right). Vero cells (B–F) transfected with pEGFP-N1 plus pcDNA3.1, Pro/S-II, Pro/S-II/Luc, Pro/S-II(LﬁA)/Luc or Pro/
S-II(QﬁA)/Luc were compared to the un-transfected cells (A). (G) Equal amounts (100 g) of cell lysates were used to determine the Luc activity
using the dual Luciferase Reporter Assay System. The reference cells transfected with pcDNA3.1 or Pro/S-II were used to subtract background noise.
Relative Luc activity in the test cells transfected with Pro/S-II/Luc, Pro/S-II(LﬁA) or Pro/S-II(QﬁA)/Luc was determined as the value of light
unitstest-reference.
136 C.-W. Lin et al. / FEBS Letters 574 (2004) 131–137the molecular interaction of the SARS-CoV 3CLpro with the
substrates, but also provides reliable assays for screening the
anti-SARS drugs.
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